Source: Health Products Regulatory Authority (ZA) Revision Year: 2019 Publisher: Sanofi-aventis south africa (pty) ltd, 2 Bond Street, Midrand, 1685, South Africa
Pharmacological classification: A 2.2 Sedatives, hypnotics.
Loprazolam is a short-acting benzodiazepine with hypnotic properties. Loprazolam has little effect on paradoxical sleep patterns (REM).
The absolute bioavailability following a single oral dose of 1 mg is 80%. The maximum concentration (Cmax) is 5,5-6,0 µg/ml per one hour (Tmax) following a single oral dose of 1 mg loprazolam.
Plasma protein binding is 80%.
Loprazolam is metabolised in the liver. The principal metabolite is the piperazine N-oxide of loprazolam.
The half-life is 6-8 hours.
In the elderly, the plasma half-life is increased (approximately 1,5 fold). Loprazolam is excreted 40% by the urinary route and 55% in the faeces, while 3-25% of the ingested dose is recovered in the bile.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
